Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease

Next Previous
Trial Profile

A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OTL 102 (Primary)
  • Indications Chronic granulomatous disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genethon

Most Recent Events

  • 13 Apr 2026 Status changed from active, no longer recruiting to discontinued.
  • 05 Apr 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2032.
  • 05 Apr 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2032.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top